Sinovac Biotech Ltd (SVA)

Sinovac Biotech Ltd develops, manufactures, and distributes vaccines against infectious diseases, with a portfolio spanning COVID-19, influenza, poliomyelitis, hepatitis, varicella, and hand-foot-and-mouth disease. Founded in China and trading on NASDAQ under ticker SVA, Sinovac has grown into one of the world’s largest vaccine producers by dose volume, serving both domestic Chinese markets and a global customer base across more than 60 countries. The company’s customers — health ministries, immunisation programs, hospitals, and individual patients — buy vaccines to prevent disease in vulnerable populations from infants to the elderly.

A vaccine-maker in a global supply chain

Sinovac makes inactivated vaccines — a technology where the virus is chemically killed before being formulated into a vaccine. This approach contrasts with mRNA vaccines (used by Pfizer and Moderna) or live-attenuated vaccines (weakened-virus forms). Inactivated vaccines are stable at refrigerator temperatures, relatively simple to manufacture at scale, and have a long track record of safety across many disease areas. For Sinovac’s customers — particularly in lower-income countries and emerging markets with limited cold-chain infrastructure — the temperature stability and manufacturing simplicity are major selling points.

The company’s vaccine portfolio spans childhood immunisations (hepatitis A, poliomyelitis, varicella, mumps), traveller vaccines, and pandemic-response products. Each vaccine requires regulatory approval in target markets, manufacturing capacity to meet demand, and a supply-chain network to distribute to clinics and hospitals. Sinovac operates manufacturing plants in China and partnerships for international distribution, positioning it to serve both domestic Chinese immunisation programs and global buyers.

CoronaVac and the pandemic windfall

The company’s most significant commercial success came with CoronaVac, its inactivated COVID-19 vaccine, which launched in 2020 and became one of the world’s most-used vaccines. Over 2.9 billion doses of CoronaVac were delivered globally, making Sinovac the largest China-based COVID-19 vaccine provider in international markets. The vaccine was approved in more than 60 countries and regions, reaching populations in Southeast Asia, Latin America, the Middle East, Africa, and Eastern Europe.

The pandemic created enormous demand and revenue for the company, as health systems and governments urgently purchased vaccines to immunise their populations. For Sinovac, this meant rapidly scaling manufacturing, managing global supply agreements, and serving as a critical supplier to regions where Western mRNA vaccines faced access or affordability barriers. The success of CoronaVac lifted Sinovac’s profile globally and generated the cash and brand recognition that enabled expansion into other vaccine areas.

Revenue and business segments

Sinovac’s revenue comes from vaccine sales, segmented by disease (COVID-19, routine vaccines like hepatitis and varicella, and emerging vaccines under development). The company also earns revenue from collaborations with research partners or other manufacturers who license its vaccine technology or manufacturing capacity. Because vaccines are purchased by governments, health ministries, and public-health programs, the customer base tends to be stable but also price-sensitive. Tender processes and volume negotiations are normal, and reimbursement rates vary widely by country and disease.

The cost structure includes research and development (for new vaccines and formulations), manufacturing and quality control (ensuring products meet regulatory standards), and distribution logistics. Vaccine manufacturing requires compliance with stringent regulatory standards, particularly for exports to developed markets with high approval bars. Sinovac maintains facilities and quality systems to meet these requirements, though manufacturing in China carries geopolitical considerations that sometimes affect market access or customer purchasing decisions.

Competitive and regulatory landscape

Sinovac competes with other vaccine makers globally, including large multinational companies like Merck and Sanofi Pasteur, as well as other Chinese and Indian vaccine manufacturers. The competitive dynamics vary by vaccine: in COVID-19, competition has intensified as the market matured from pandemic urgency to endemic disease management and booster campaigns. In routine vaccines like hepatitis, Sinovac competes on price and regulatory acceptance in target markets.

Regulatory approval is a key constraint on growth. Each vaccine and each country require separate regulatory pathways, clinical trials, and manufacturing inspections. Sinovac has worked to secure approvals in major markets, including the European Union and the United States, though full licensing in some developed countries remains limited. The company’s primary addressable markets are China (where it supplies government immunisation programs) and emerging markets where inactivated vaccines are preferred or where price is a decisive factor.

Risks and recent developments

The shift from pandemic to endemic COVID-19 poses a significant headwind: demand for COVID-19 vaccines has declined sharply from peak pandemic levels, and CoronaVac revenue will compress. The company is transitioning to routine booster markets and expanding into other vaccines to offset this decline. In May 2026, Sinovac received approval to launch clinical trials for an influenza vaccine, indicating efforts to expand beyond COVID-19.

Geopolitical tensions around China also introduce risk. Some markets restrict purchases from Chinese suppliers or prefer diversified sourcing away from any single country. Taiwan relations, supply-chain dynamics, and Western regulatory skepticism toward Chinese biologics can all affect Sinovac’s ability to serve certain markets or secure long-term supply agreements.

How to research Sinovac

The company files an annual 10-K (SEC CIK 0001084201) detailing revenue by vaccine type, manufacturing capacity, regulatory approvals, and pipeline developments. Quarterly earnings calls provide color on demand trends, geographic sales mix, and progress on new vaccine candidates. Track CoronaVac revenue explicitly — watch whether it is declining (as expected post-pandemic) and at what pace, and whether new vaccines are filling the gap.

Monitor press releases and SEC filings for updates on clinical trials, regulatory approvals in major markets, and partnership announcements. Because the company operates in China, read about any policy changes affecting China’s vaccine distribution, export policies, or regulatory environment. Industry reports on global vaccine supply, disease prevalence trends, and public-health spending also inform Sinovac’s opportunity set and competitive position.